UPDATE -- athenahealth Announces Industry’s First MIPS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
UPDATE -- athenahealth Announces Industry’s First MIPS Guarantee

WATERTOWN, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ: ATHN ), a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced its Merit-Based Incentive Payment System (MIPS) Guarantee, which aims to shield healthcare providers and practices from downward payment adjustments under the proposed Medicare reimbursement program of the same name.  The guarantee comes months ahead of the Centers for Medicare and Medicaid Services’ (CMS) release of the final MACRA rule and amidst mounting debate over reimbursement change and complexity.   

“At a time when nearly all providers across the U.S. are expected to keep up with ever-changing reimbursement rules and an estimated 45 percent of those who bill Medicare Part B are facing payment cuts under the MIPS program, we’re looking to lift the burden,” said Jonathan Bush, chief executive officer, athenahealth. “The complexity of government reimbursement is just too onerous; and, it’s not something providers or practice staff should have to master. Because of our national network, our quality management and payer rules engine, our team of experts, and our track record of client success as part of other government-run programs, we believe we can free the industry of reimbursement cuts associated with MIPS. And if we can’t, we’ll put our money where our mouth is and reimburse clients up to the penalty amount.”

athenahealth’s MIPS Guarantee continues a history of industry-leading guarantee programs offered by the company for government-mandated quality reporting, including a 97.6% 2015 Meaningful Use (MU) attestation rate and 98.9% avoidance of Physician Quality Reporting System (PQRS) and Value Modifier (VM) penalties in 2016.

What is MIPS?

Part of the new Medicare physician payment system established by the Medicare Access and CHIP Reauthorization Act (MACRA), MIPS streamlines existing quality reporting programs and links fee-for-service payments to quality and value by commanding 4 percent Medicare payment adjustments. An estimated 90% of eligible clinicians billing Medicare Part B will qualify for MIPS and are required to participate in the program by 2017, with payment adjustments set to take effect in 2019.   

What is athenahealth guaranteeing?

athenahealth’s network-enabled athenaOne® services will feature workflows and native intelligence designed to manage quality, collect data, and handle reporting for MIPS, minimizing work and risk for practices of all sizes and specialties.  Under athenahealth’s MIPS Guarantee, new practices using athenaOne are guaranteed to perform at or above the national performance threshold set by CMS and avoid payment penalties to their Medicare Part B fee schedule. athenahealth will cover penalties for those practices that are not successful subject to certain limitations. [1]  

“Before the ink has even dried on the MIPS Guarantee, athenahealth is sticking its neck out for providers and extending the reach of what has become our company’s unique hallmark: partnership, and aligned incentives,” continued Bush. “MIPS represents CMS’ unsubtle change in approach from “carrot” to “stick.”  athenahealth is standing up to potentially bear the brunt of that stick’s whack, going at risk ourselves to manage the administrative technocracy so that doctors can be doctors. With so much uncertainty about how the MIPS program will unfold and what consequences it will have on health care, this is the boldest expression of athenahealth’s commitment to providers yet: we only succeed when they succeed.  CMS has been unable to commit to a firm timeline for implementation, but athenahealth’s line in the sand is clear: We will help providers of all sizes and specialties clear this latest hurdle as we continue our work in service of an even larger goal, to unbreak healthcare.”

To learn more about athenahealth’s MIPS Guarantee, please visit www.athenahealth.com/guarantee/mips

1  The MIPS 2017 Guarantee is only available to new athenahealth clients that go live on athenaOne services by June 30, 2017. Client must agree to Guarantee terms in an effective services agreement between Athena and Client. If all conditions in the Guarantee terms are met, and our athenaOne clients experience a MIPS payment penalty (downward fee adjustment) based on MIPS Performance during the applicable Reporting Year, Athena will provide monthly service credits to Client through the end of the relevant MIPS year, provided that the amount of any such Credit shall not exceed Client’s total monthly athenaOne Service Fee with respect to such month; provided that if the agreement between the parties expires or terminates prior to Client receiving the full Credit amount, the Client shall forfeit the remainder of the Credit amount; and provided that the Credits will be the Client’s sole and exclusive remedy with respect to any downward payment adjustment to Client’s Medicare fee schedule during the applicable MIPS year. Additional conditions apply and Clients should review the Guarantee terms in their services agreement.

About athenahealth, Inc. athenahealth is a leading provider of cloud-based services for electronic health records ( EHR ), revenue cycle management and   medical billing , patient engagement , care coordination , and population health management, as well as Epocrates and other point-of-care mobile apps. We connect care and drive meaningful, measurable results for more than 80,000 health care providers in medical practices and health systems nationwide. For more information, please visit www.athenahealth.com .

Forward-Looking Statements This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, for example, statements regarding the ability of the company to shield healthcare providers and practices from downward payment adjustments, to free the industry of reimbursement cuts associated with MIPS, and to unbreak healthcare. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  athenahealth undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by athenahealth, please see the disclosure contained in our public filings with the Securities and Exchange Commission (SEC), available on the Investors section of our website at http://www.athenahealth.com  and on the SEC's website at http://www.sec.gov .

Contact Info: Holly Spring athenahealth, Inc. (Media) media@athenahealth.com 617-402-1631 Dana Quattrochi athenahealth, Inc. (Investors) investorrelations@athenahealth.com 617-402-1329

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading